StockData
Zevra Therapeutics, Inc. logo

Zevra Therapeutics, Inc. (ZVRA) stock

ZVRANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 15/3060% below fair value
$9.40+0.15 (+1.62%)

Close on Nov 17, 2026Market cap $558.21MP/E 10.1Yield –

Zevra Therapeutics enterprise value

Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.

Zevra Therapeutics's enterprise value was $481.63M on Nov 11, 2026, against $335.72M a year earlier. Over the last 5 years it ranged from $44.13M to $647.09M, with a median of $217.31M.

Enterprise Value at the end of each year

PeriodPeriod endValueChange
2026Nov 11, 2026$481.63M+31.8%
2025Dec 31, 2025$365.51M-11.6%
2024Dec 31, 2024$413.44M+159.5%
2023Dec 29, 2023$159.32M+93.2%
2022Dec 30, 2022$82.47M-53.2%
2021Dec 31, 2021$176.11M+280.6%
2020Dec 31, 2020$46.27M+702.5%
2019Dec 31, 2019$5.77M-62.9%
2018Dec 31, 2018$15.53M+19.2%
2017Dec 29, 2017$13.02M–
2016Dec 30, 2016-$21.42M-109.6%
2015Dec 31, 2015$223.83M–

More Zevra Therapeutics figures

See a number that looks wrong?